Themes: European operations
With cheaper copies of Cipralex hitting the market, the central nervous system experts at Lundbeck had little choice but to restructure their European operations over the summer, announcing plans to cut 600 jobs. The goal is to get more "flexible" about detailing to primary care, while pushing experimental drugs through the pipeline to make up for lost revenue.
Company executives have highlighted the potential for Onfi (clobazam), an epilepsy drug slated for an FDA filing in the fourth quarter, and the alcohol-dependence drug nalmefene, which is expected to be filed in Europe by the end of this year. And Lundbeck and Takeda filed their NDA for vortioxetine (formerly known as Lu AA21004)--intended for the treatment of major depressive disorder in adult patients--at the beginning of October.
R&D hasn't escaped the ax, though. Last year, Lundbeck followed up with a plan to lay off 175 of its 1,400 research workers in Denmark and Paramus, NJ. It's all part of the flexibility campaign at Lundbeck, only in this case, that means firing staffers while boosting outsourcing with CROs.
Special Report: Lu AA21004/vortioxetine - Blockbuster buzz: 15 top therapies in late-stage development
Austerity, generics push Lundbeck to cut 600 jobs
Lundbeck banks on pipeline as antidepressant sales skid
Lundbeck, Otsuka scramble to get antipsychotic back on FDA track